Comment
doi: 10.1038/ki.2013.549.
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Affiliations
- PMID: 24583981
- DOI: 10.1038/ki.2013.549
Item in Clipboard
Comment
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Kidney Int.
2014 Mar.
Free article
Abstract
A soluble proteinuric substance has been postulated as a cause of primary focal segmental glomerulosclerosis (FSGS), and one candidate soluble urokinase receptor (suPAR). Evaluation of published results shows that serum suPAR determinations by current methodology do not reliably distinguish FSGS from other proteinuric glomerular diseases and serum suPAR cannot currently be considered a valid biomarker for primary or secondary FSGS. However, this should not discourage further research on potential roles of suPAR in proteinuric renal disease, including FSGS.
Comment on
-
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.Kidney Int. 2014 Mar;85(3):636-40. doi: 10.1038/ki.2013.505. Epub 2014 Jan 8. Kidney Int. 2014. PMID: 24402090
-
A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.Kidney Int. 2014 Mar;85(3):641-8. doi: 10.1038/ki.2013.544. Epub 2014 Jan 15. Kidney Int. 2014. PMID: 24429394
-
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15. Kidney Int. 2014. PMID: 24429405
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
